April 5, 2024

Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

To evaluate the impact of depressive symptom severity on opioid use and treatment retention in individuals with prescription-type opioid use disorder (POUD).

Me gusta

Guardar

Cite This Study

Bastien et al. (Fri,) studied this question.

synapsesocial.com/papers/68e7044fb6db64358767dbdb https://doi.org/https://doi.org/10.1080/15504263.2024.2329267

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Prospective Study of Depression and the Risk of Heavy Alcohol Use in Women2000 · 183 citations
2[Predictive factors of response to buprenorphine in the substitutive treatment of heroin addicts. Results of a multicenter study of 73 patients].2001 · 12 citations
3A Double-Blind, Placebo-Controlled Trial Combining Sertraline and Naltrexone for Treating Co-Occurring Depression and Alcohol Dependence2010 · 262 citations
4The Influence of Coping and Depression on Abstinence from Illicit Drug Use in Methadone-Maintained Patients2000 · 41 citations
5Evidence synthesis - The opioid crisis in Canada: a national perspective2018 · 434 citations

Me gusta

Guardar